Jul 31, 2023
Immutep Quarterly Activities Report Q4 FY23
Jul 28, 2023
First Patient Dosed in Chemotherapy-Free Triple Combination Phase II Trial Targeting Soft Tissue Sarcoma
Jun 27, 2023
Immutep Secures Third United States Patent for Eftilagimod Alpha in Combination with a PD-1 Pathway Inhibitor
Immutep Completes A$80 Million Capital Raise
Jun 20, 2023
Immutep Granted United States Patent for IMP761, a First-in-Class Agonist Antibody Targeting LAG-3
